Recursion Pharmaceuticals Inc (NASDAQ: RXRX) kicked off on Monday, up 2.14% from the previous trading day, before settling in for the closing price of $7.49. Over the past 52 weeks, RXRX has traded in a range of $5.60-$15.74.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
During the last 5-year period, the sales growth of Healthcare Sector giant was 132.77%. While this was happening, its average annual earnings per share was recorded 2.61%. With a float of $322.93 million, this company’s outstanding shares have now reached $390.76 million.
In terms of profitability, gross margin is 3.01%, operating margin of -620.35%, and the pretax margin is -583.75%.
Recursion Pharmaceuticals Inc (RXRX) Breakdown of a Key Holders of the stock
Our next focus will be how large-scale investors are participating in this stock of the Biotechnology Industry. The insider ownership of Recursion Pharmaceuticals Inc is 17.36%, while institutional ownership is 58.46%. The most recent insider transaction that took place on Feb 06 ’25, was worth 162,400. In this transaction Chief Executive Officer of this company sold 20,000 shares at a rate of $8.12, taking the stock ownership to the 1,273,156 shares. Before that another transaction happened on Feb 05 ’25, when Company’s Chief Executive Officer sold 20,000 for $7.68, making the entire transaction worth $153,600. This insider now owns 1,273,156 shares in total.
Recursion Pharmaceuticals Inc (RXRX) Recent Fiscal highlights
Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.48 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 2.61% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 4.49% during the next five years compared to -43.41% drop over the previous five years of trading.
Recursion Pharmaceuticals Inc (NASDAQ: RXRX) Trading Performance Indicators
Take a look at Recursion Pharmaceuticals Inc’s (RXRX) current performance indicators. Last quarter, stock had a quick ratio of 4.35. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 45.86.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -1.53, a number that is poised to hit -0.41 in the next quarter and is forecasted to reach -1.65 in one year’s time.
Technical Analysis of Recursion Pharmaceuticals Inc (RXRX)
Looking closely at Recursion Pharmaceuticals Inc (NASDAQ: RXRX), its last 5-days average volume was 29.83 million, which is a jump from its year-to-date volume of 19.53 million. As of the previous 9 days, the stock’s Stochastic %D was 43.73%. Additionally, its Average True Range was 0.69.
During the past 100 days, Recursion Pharmaceuticals Inc’s (RXRX) raw stochastic average was set at 51.90%, which indicates a significant decrease from 59.62% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 80.00% in the past 14 days, which was lower than the 85.99% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $7.13, while its 200-day Moving Average is $7.42. However, in the short run, Recursion Pharmaceuticals Inc’s stock first resistance to watch stands at $8.01. Second resistance stands at $8.36. The third major resistance level sits at $8.63. If the price goes on to break the first support level at $7.39, it is likely to go to the next support level at $7.12. Now, if the price goes above the second support level, the third support stands at $6.77.
Recursion Pharmaceuticals Inc (NASDAQ: RXRX) Key Stats
The company with the Market Capitalisation of 2.99 billion has total of 390,722K Shares Outstanding. Its annual sales at the moment are 44,580 K in contrast with the sum of -328,070 K annual income. Company’s last quarter sales were recorded 26,080 K and last quarter income was -95,840 K.
